LYT-310

< RETURN

Our programs

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

LYT-310

Oral Cannabidiol

Epilepsies & other neurological indications

Phase:
Preclinical

Initial Indications:
Epilepsies & other neurological indications

Patient Population:

Key Differentiations:

Therapeutic candidate designed to unlock the validated efficacy of cannabidiol (CBD). Derived from the Glyph platform, LYT-310 offers oral dosing and the potential for improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other central nervous system disorders.

More about LYT-310

Phase completed

Phase in progress

¹ The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that LYT-310 is safe or effective for use by the general public for any indication.

An oral form of cannabidiol (CBD) for the potential treatment of neurological conditions

Using our Glyph™ platform (see here), which harnesses the natural transport of dietary lipids via the lymphatics, we have developed LYT-310, an oral form of CBD. By transporting CBD via the lymphatics, LYT-310 is designed to offer oral dosing and improved tolerability, which could expand the therapeutic application of CBD across a wider range of age groups and indications, including both rare and more common forms of epilepsy and other central nervous system disorders.

Key Points of Innovation & Differentiation
LYT-310 is designed to greatly expand the therapeutic application and potential of CBD by:
- enabling oral administration in a capsule;
- expanding the use of CBD into a broad range of therapeutic areas and patient populations (such as adolescents and adults) where higher doses are required to achieve a therapeutic effect;
- potentially improving safety and reducing gastrointestinal (GI) tract side effects that are associated with the currently approved CBD-based treatment by reducing GI and liver exposure; and
- allowing for a readily scalable, consistent product in a cost-effective manner.
Program Discovery Process by the PureTech Team
- LYT-310 is the second therapeutic candidate developed from our synthetic lymphatic-targeting chemistry platform called Glyph (see here), which employs the body’s natural lipid absorption and transport process to orally administer drugs via the lymphatic system.
Patient Need & Market Potential
- A CBD-based product has received regulatory approval in the United States and Europe to treat seizures resulting from certain rare conditions, but it requires a large volume of a sesame oil-based formulation, which limits its use in broader indications and age groups.
Milestones Achieved & Development Status
- In multiple preclinical models, including large animal and non-human primate, LYT-310 has demonstrated a three to fourfold increase in oral exposure vs. unmodified CBD in a fasted state. This has the potential to translate into improved safety and reduced side effects. Lymphatic transport has also been confirmed in preclinical models, with up to 30% of LYT-310 entering the lymphatics, compared to 5% for unmodified CBD – which further supports the novel Glyph mechanism of enhancing bioavailability.
Expected Milestones
- We are advancing LYT-310 towards clinical studies, which are expected to begin in Q4 of 2023.

Press Releases

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech's Glyph™ Platform

November 30, 2022